Abstract:
Introduction: Acute myocardial infarction is the most important and feared consequence of coronary artery disease. STEMI is the one of that kind and it occurs by formation of a vulnerable plaque from atherosclerosis and transforms into coronary artery thrombosis in the end. Streptokinase has been used as a thrombolytic agent in patients with acute STEMI. It combines with the circulatory plasminogen to form an activator complex and it converts into plasmin, where, the plasmin breaks the fibrin complex in the blood clot. Streptokinase can be given as 1,500,000U a slow I.V infusion over 30 min. Each STEMI subject is different with the aetiology, pain, ST segment elevation. By considering these factors the clinical efficacy of streptokinase will be evaluated. Materials and Methods: A total number of 75 subjects presenting with acute STEMI to the department of cardiology, King George Hospital, Visakhapatnam, and, those were thrombolysed with streptokinase are included in the study. pain was assessed before and 90 min after administration of streptokinase on numerical pain rating scale from 0-10. ST segment resolution was assessed as percentage reduction in ST segment elevation before administration of streptokinase and the reduction of ST segment elevation 90 min after administration of streptokinase. Student t-test and chi-square test were applied to evaluate the results by using software SPSS. Results: A significant resolution in the pain and ST segment elevation were identified by comparing the numerical pain rating scale and ST segment elevation on pre and post streptokinase administration. Conclusion: Streptokinase has been shown to have significant effect on pain resolution and ST segment resolution in subjects with acute ST segment elevation myocardial infarction.
Key words: Acute ST segment elevation myocardial infarction, Clinical efficacy, Pain, Streptokinase, ST segment elevation, Thrombolysed subjects.
